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Abstract
Efavirenz-based first-line regimens have been widely used for children�3 years of age start-
ing antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside
reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We
used logistic regression to examine the association between PMTCT exposure and viral fail-
ure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6–18 months
on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF
compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).
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Regional data comprises cohorts within Southern
Introduction
While prevention of mother to child HIV transmission (PMTCT) has greatly reduced the
number of new pediatric HIV infections, there are still 1.8 million children <15 years of age
living with HIV both due to ongoing mother-to-child transmission, and survival of children
living with HIV. Over 80% of these children live in sub Saharan Africa (SSA) [1]. Despite rec-
ommendations and guidelines by World Health Organisation (WHO) to treat all people living
with HIV irrespective of age and CD4 count [2], optimal antiretroviral therapy (ART) dosing
and formulations across all pediatric weight bands and age groups is still a challenge [3]. Meta-
bolic and pharmacokinetic changes related to child development and puberty may require dif-
ferent dosing requirements for children compared to adults [4]. While dolutegravir (DTG)
provides hope for simplification and harmonization of pediatric and adult regimens, it is still
also not recommended for younger children below 30 kilograms (kgs) and for some children
above three years of age [3–5].
In resource limited settings, efavirenz (EFV) will remain part of first-line pediatric regimens
and is likely to continue to be relatively widely used [6]. In addition, EFV may be preferred in
children requiring rifampicin-based tuberculosis co-treatment [7] and among female adoles-
cents of child bearing age who are not on any, or have inconsistent use of contraception [8].
EFV has been recommended for older children (>3 years) and adults for several years due to
its advantages for long term maintenance, once daily dosing, simplification of co-treatment for
tuberculosis and preserving alternative drugs for second-line [9].
However, the number of children living with HIV initiating first-line non-nucleoside reverse
transcriptase inhibitor (NNRTI) treatment with pre-treatment drug resistance (PDR) due to
prior exposure to maternal or infant PMTCT regimens is a significant challenge [9, 10]. Both
NVP and EFV have a low genetic barrier to resistance and nevirapine (NVP) remains part of
WHO-recommended infant prophylaxis during breastfeeding. Y181C is the most commonly
selected mutation following NVP exposure which confers high-level resistance to NVP and
low-level resistance to EFV [10]. Kityo et al. reported that 1 in 6 children initiating first line
ART (164/278 on EFV, 104/278 on NVP and 10/278 on protease inhibitor (PI)) in Uganda had
PDR; children with PDR were 15 times more likely to experience virologic failure compared to
those without. Children with prior or unknown PMTCT exposure were more likely to have
PDR, and although PDR proportions were high, they may have been underestimated due to
archived resistance in older children [11]. Among Nigerian children initiating treatment, 16%
had PDR and among these 33% experienced treatment failure by 24 months on treatment [12].
The Nevirapine Resistance trial (NEVEREST III) showed non-inferior virologic outcomes
(viral failure or rebound) for children < 3years old initiating lopinavir-based first-line and
switching to an EFV-based regimen at 3–5 years of age [9]. In both of these studies very few
children had extended infant NVP prophylaxis, so the prevalence of PDR and subsequent viro-
logic outcomes (virologic suppression or failure) on EFV-based first-line in this context are
not known.
Our study aimed to investigate the association between PMTCT exposure and viral failure
in children aged at least three years starting EFV-based ART using routine data from the Inter-
national epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) collaboration.
Materials and methods
Study setting and population
We used data from IeDEA-SA, a regional collaboration of adult and pediatric HIV treatment
programs [13]. We included all children living with HIV aged 3–13 years who initiated EFV-
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based ART between 2004 and 2014 at 10 public sector ART programs in South Africa and who
had at least two viral load (VL) measurements from six-18 months on ART.
Exposure and outcome definition
PMTCT exposure status was recorded as exposed, unexposed or unknown. Actual PMTCT
regimens were not consistently recorded but the data contained a variable differentiating
between those that had been exposed to PMTCT or not based on mother-to child data linkage.
Maternal and child PMTCT regimens from relevant South African national and provincial
guidelines over the study period are shown in S1a Table and S1b Table in S1 File.
We defined viral failure (VF) as having two consecutive VLs� 1000 copies/ml in the 6–18
months after ART initiation. We further present results for the outcome of VF defined as two
consecutive VLS� 400 copies/ml in the follow up period. We also present results on virologic
non-suppression in S5 Table and S6 Table in S1 File for both cut offs respectively. This was
defined as the maximum viral load above 1000 copies/ml in the 6–18 months window to occur
(one line per patient was considered). For children with more than 2 values, the worst (highest)
value was considered as either suppressed or unsuppressed depending on whether or not it
was above 1000 copies/ml.
Statistical analysis
Descriptive statistics (means (standard deviation), medians (interquartile range) and propor-
tions) were used to summarize patient characteristics. We examined the association between
PMTCT exposure and VF between 6–18 months on ART using logistic regression and adjust-
ing for other patient characteristics including calendar year of ART start. Since no PMTCT
was available in the public sector in South Africa before 2000, we assumed that children with
unknown PMTCT exposure born before 2000 were PMTCT unexposed.
In sensitivity analyses for those born during or after 2000, we assumed PMTCT exposure
for those with unknown exposure was either: (1) all exposed as per South African PMTCT
guidelines at the time of the child’s birth or (2) all unexposed. Results presented are based on
complete case analysis(CCA). Multiple imputation (MI) of missing data on WHO stage and
immunosuppression using 10 imputed datasets was also done and the results were combined
using Rubin’s rules. There was no difference in the results between the CCA and MI for both
outcomes of VF (2 consecutive VL�1000 copies/ml or 400 copies/ml respectively) (S2 Table–
S4 Table in S1 File). All analysis was done using STATA version 15.1.
Ethics
IeDEA-SA cohorts have obtained ethical approval to collect and transfer anonymized data
through their respective Institutional Review Boards (IRBs). The IeDEA-SA data centre has
approval from the University of Cape Town’s IRB (Human Research Ethics Committee
(HREC)) to receive and analyse these anonymised data.
Results
Of the 7,896 children included in the analysis, 3,948 (50%) were girls with a median age at
ART start of 7.5 (IQR: 5.3, 10.2) years. Over two thirds 5,282/7,896 (66.9%) of the children had
initiated ART with World Health Organisation (WHO) clinical stage 3 or 4 disease, and 2,320
(40.1%) had WHO-defined severe immunosuppression (Table 1).
Recorded PMTCT exposure was: 5,909 (74.8%) unexposed, 529 (6.7%) exposed and 1,458
(18.5%) unknown. After assuming that those with unknown exposure received PMTCT
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according to the year of birth, there were a total of 17.9% (1,413/7896) exposed. Overall, VF
was experienced by 1,224/7896 (15.5%) in the period of 6–18 months on ART, and among
these, 1,021 (83.4%) had no PMTCT exposure, 61 (5.0%) had been exposed to PMTCT and
142 (11.6%) had unknown exposure to PMTCT.
Table 1. Characteristics of children stratified by three prevention of mother-to-child transmission (PMTCT) exposure scenarios:- i) according to clinic records,
“unknown” category allocated to ii) PMTCT according to national guidelines at the year of birth (YoB) and iii) not receiving PMTCT.
PMTCT exposure status according to the
clinic records$
Unknown PMTCT allocated to PMTCT
exposure according to the year of birth$





















Female 3093 (50.6) 261 (49.3) 1007 (49.5) 3283 (50.6) 682 (48.3) 3965 (50.2) 3706 (50.3) 259 (49.5) 3965 (50.2)
WHO Stagea, n (%)
Stages 1&2 1372 (36.1) 34 (15.0) 274 (26.4) 1472 (35.2) 208 (23.4) 1680 (33.1) 1650 (34.0) 30 (13.6) 1680 (33.1)
Stages 3&4 2434 (64.0) 192 (85.0) 766 (73.7) 2711 (64.8) 681 (76.6) 3392 (66.9) 3200 (66.0) 192 (86.5) 3392 (66.9)
WHO defined
immunosuppression�, n (%)
No 2393 (57.4) 296 (68.4) 773 (65.3) 2682 (57.7) 780 (68.6) 3462 (59.9) 3169 (59.2) 293 (68.1) 3462 (59.9)
Yes 1773 (42.6) 137 (31.6) 410 (34.6) 1963 (42.3) 357 (31.4) 2320 (40.1) 2183 (40.8) 137 (31.9) 2320 (40.1)
Year of antiretroviral therapy
(ART) start, n (%)
2004–2005 925 (15.1) 20 (3.8) 319 (15.7) 979 (15.1) 75 (5.3) 1054 (13.4) 1034 (14.0) 20 (3.8) 1054 (13.4)
2006–2007 1076 (17.6) 81 (15.3) 530 (26.0) 1176 (18.1) 252 (17.9) 1428 (18.1) 1348 (18.3) 80 (15.3) 1428 (18.1)
2008–2009 1236 (20.2) 159 (30.1) 563 (27.7) 1338 (20.6) 417 (29.5) 1755 (22.2) 1598 (21.7) 157 (30.0) 1755 (22.2)
2010–2011 1252 (20.5) 155 (29.3) 395 (19.4) 1328 (20.5) 386 (27.3) 1714 (21.7) 1560 (21.2) 154 (29.5) 1714 (21.7)
2012–2014 1625 (26.6) 114 (21.6) 228 (11.2) 1663 (25.7) 282 (20.0) 1945 (24.6) 1833 (24.9) 112 (21.4) 1945 (24.6)
Year of birth, n (%)
Before 2000 1668 (31.3) 0 (0.0) 782 (38.4) 2450 (37.8) 0 (0.0) 2450 (1.0) 2450 (33.2) 0 (0.0) 2450 (31.0)
2000–2003 2184 (40.9) 239 (45.2) 829 (40.7) 2554 (39.4) 698 (49.4) 3252 (41.2) 3016 (40.9) 236 (45.1) 3252 (41.2)
2004–2005 685 (12.9) 171 (32.3) 271 (13.3) 685 (10.6) 442 (31.2) 1127 (14.3) 958 (13.0) 169 (32.3) 1127 (14.3)
2006–2007 479 (9.0) 69 (13.0) 111 (5.5) 479 (7.4) 180 (12.8) 659 (8.4) 591 (8.0) 68 (13.0) 659 (8.4)
2008–2009 248 (4.7) 46 (8.7) 35 (1.7) 248 (3.8) 81 (5.7) 329 (4.2) 283 (3.8) 46 (8.8) 329 (4.2)
2010 and beyond 68 (1.3) 4 (0.8) 7 (0.3) 68 (1.1) 11 (0.8) 79 (1.0) 75 (1.0) 4 (0.8) 79 (1.0)
Weight for age Z- score, (Mean
(SD))
-1.68 (1.30) -1.61 (1.22) -1.39 (1.22) -1.48 (1.30) -1.28 (1.26) -1.43 (1.29) -1.44 (1.31) -1.37 (1.21) -1.43 (1.29)




















PMTCT infant drug, n (%)
sdNVP 480 (90.6) 1329 (94.1) 479 (91.6)
sdNVP+AZT 42 (7.9) 76 (5.4) 42 (8.0)
NVP 6 weeks 2 (0.4) 7 (0.5) 2 (0.4)
Unknown 5 (1.0) 2035 (100.0)
Maternal PMTCT regimen, n
(%)
sdNVP 0 (0.0) 474 (89.6) 0 (0.0) 1285 (91.0) 474 (90.6)
sdNVP + AZT 0 (0.0) 45 (8.5) 0 (0.0) 126 (8.9) 45 (8.6)
AZT only 0 (0.0) 10 (1.9) 2035 (100.0) 1 (0.0) 0 (0.0) 1 (0.01) 0 (0.0)
$Children born before 2000 with unknown PMTCT exposure (n = 782) assumed to get no PMTCT as no PMTCT was available in the public sector before 2000.
aMissing observations for 2824/ 7896 (35.8%),
�Missing observations for 2114/7896 (26.8%) of children of children
https://doi.org/10.1371/journal.pone.0233693.t001
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After adjusting for immunosuppression, calendar year at ART start, age at ART start as a
continuous variable and the year of birth (Table 2), children with previous PMTCT exposure
did not have higher odds of experiencing VF compared to unexposed children (adjusted Odds
Ratio (aOR): 0.79; 95% CI: 0.56, 1.11). In sensitivity analyses, after assuming children with
unknown PMTCT exposure received PMTCT according to South African guidelines at the
time and adjusting for the above covariates, there continued to be no evidence of increased
odds of VF in PMTCT exposed compared to unexposed children (aOR:0.66; 95%CI:
0.52,0.85). Likewise, if those of unknown PMTCT exposure were assumed to have received no
PMTCT, there was also no evidence of increased odds of VF (aOR:0.91; 95% CI: 0.65, 1.27)
respectively. Furthermore, sensitivity analysis looking at a cut off of� 400 copies/ml for VF
yielded similar results (S3 Table in S1 File).
Table 2. Univariable and multivariable models of association between prevention of mother-to-child transmission (PMTCT) exposure and viral failure (VF)
defined as two consecutive viral load (VL)�1000 copies/ml between 6–18 months on ART: Analysis based on 5782 patients.
Patient characteristics at ART start Univariable associations No assumptions made for
unknown PMTCT$
Assumption I: Unknown got
PMTCT according to year of
birth
Assumption II: Unknown
assumed not to have got any
PMTCT
Crude OR� 95% CI�� Adjusted OR� 95% CI�� Adjusted OR� 95% CI�� Adjusted OR� 95% CI��
PMTCT exposure status
No 1 1 1 1
Yes 0.62 0.47, 0.82 0.79 0.56, 1.11 0.66 0.52, 0.85 0.91 0.65, 1.27
Unknown 0.52 0.43, 0.62 0.55 0.43, 0.69
Sex
Male 1 1 1 1
Female 0.96 0.85, 1.08 0.94 0.81, 1.09 0.94 0.81, 1.09 0.94 0.81, 1.10
WHO Stage
Stages 1&2 1
Stages 3&4 1.06 0.91, 1.24
WHO-defined Immunosuppression
No 1 1 1 1
Yes 2.14 1.82, 2.53 1.75 1.50, 2.04 1.75 1.51, 2.04 1.76 1.51, 2.04
Calendar Year of ART start
2004–2005 1 1 1 1
2006–2007 0.87 0.69, 1.09 0.88 0.68, 1.15 0.86 0.66, 1.12 0.83 0.64, 1.08
2008–2009 0.64 0.51, 0.81 0.62 0.45, 0.84 0.60 0.44, 0.82 0.57 0.42, 0.77
2010–2011 1.45 1.18, 1.79 1.54 1.08, 2.17 1.48 1.05, 2.09 1.39 0.99, 1.96
2012–2014 1.34 1.09, 1.64 1.28 0.82, 1.97 1.24 0.80, 1.91 1.19 0.77, 1.84
Year of birth
Before 2000 1 1 1 1
2000–2003 0.82 0.71, 0.94 0.84 0.64, 1.10 0.83 0.64, 1.09 0.80 0.61, 1.05
2004–2005 0.60 0.49, 0.74 0.72 0.46, 1.13 0.78 0.50, 1.21 0.73 0.47, 1.13
2006–2007 0.72 0.57, 0.92 0.85 0.49, 1.46 0.92 0.53, 1.58 0.89 0.52, 1.53
2008 and beyond 0.76 0.57, 1.02 1.00 0.50, 1.99 1.12 0.56, 2.21 1.11 0.56 2.19
Age at ART start in years 1.12 1.10, 1.15 1.05 0.99 1.11 1.06 1.00, 1.11 1.07 1.02, 1.13
$Children born before 2000 with unknown PMTCT exposure (n = 782) assumed to get no PMTCT as no PMTCT available in the public sector before 2000
�Odds Ratios.
�� Confidence Intervals.
#All models have been adjusted for sex, immunosuppression at ART start, calendar of ART start, year of birth and age at ART start
https://doi.org/10.1371/journal.pone.0233693.t002
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Discussion
Our study showed no evidence of an increased risk of VF among children who were exposed
to PMTCT starting EFV-based ART at�3 years of age. There continued to be no evidence of
an increased risk in a sensitivity analysis assuming children with unknown PMTCT exposure
either received no PMTCT or received the PMTCT regimen available at the time of their birth.
Our results concur with the NEVEREST III randomized clinical trial (RCT) which random-
ized PMTCT-exposed children to an EFV-based regimen or to continue lopinavir/ritonavir-
based ART [9]. This trial showed no increased risk of VF when virologically-suppressed chil-
dren above three years old on lopinavir-based regimens with prior single dose NVP-based
PMTCT exposure were switched to EFV-based regimens. Podjanee et al in Thailand also
found a similar association of no difference in VF risk based on PMTCT exposure, with a
quarter of the children with and without PMTCT exposure experiencing VF during the study
period [14].
As children had to be at least three years old at ART start to initiate an EFV-based regimen
according to South African guidelines, there were only 11 children with documented PMTCT
exposure after the introduction of extended infant NVP prophylaxis, hence we were unable to
determine the effect of prolonged infant NVP on outcomes for subsequent EFV-based ART,
although none of the 11 children experienced VF. Nonetheless, it is hypothesized that since a
single mutation confers EFV resistance and almost all single-dose NVP-exposed infants har-
bour one of these mutations, longer durations of infant NVP are unlikely to worsen subse-
quent EFV-based ART outcomes. While some studies have suggested worse outcomes for
PMTCT-exposed children on NNRTI-based ART, most PMTCT-exposed children in these
studies would have been treated with NVP-based rather than EFV-based ART [15, 16].
Regardless of our findings, the high prevalence of HIV drug resistance to NNRTIs, as a result
of the low genetic barrier to resistance, is a major challenge with NNRTI use, specifically EFV,
and children receiving EFV should be closely monitored for adherence and viral suppression.
Even with the increasing rollout of DTG for treatment of children living with HIV, many
resource-limited settings in SSA and Asia will continue to use EFV in younger children and
women or adolescent girls of child bearing age. In addition to the concerns regarding resis-
tance, EFV is reported to have adverse side effects like central nervous system toxicity although
this is more mild in children than it is in adults [17]. There are also additional potential side
effects such as impaired concentration, skin rash, dizziness, sleep disturbances and anxiety [18,
19]. PI-based first line therapy may offer better outcomes compared to the NNRTIs [20–22]. It
is important to have options for first line ART in children and challenges with lopinavir/rito-
navir include poor palatability, increased abdominal side effects (diarrhoea and nausea), drug-
drug interactions with rifampicin co-treatment and the increased cost and lack of improved
paediatric formulations.
Our study had several limitations. Although we adjusted for pre-ART patient characteris-
tics and calendar time, there may be other factors (structural, clinical or psychosocial) related
to access to PMTCT that are also associated with better ART outcomes. While this may par-
tially explain the reduced VF associated with PMTCT exposure when assuming that all chil-
dren with unknown PMTCT exposure received PMTCT according to the year of birth, these
factors may also have introduced confounding and potentially masked an association
between PMTCT and worse ART response. In addition, since we relied on routinely col-
lected cohort data, we did not have data on other variables that may impact the outcome
such as adherence, breastfeeding and cotrimoxazole use, so could not adjust for these vari-
ables. We also do not have data regarding the reasons for failing PMTCT. We also only
included children that had�2 VL measurement between 6 and 18 months on ART. This
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may have introduced selection bias given there may be children who potentially experienced
VF but had <2 VL results.
While the use of data from routine care settings in South Africa makes our results generaliz-
able, the recording of PMTCT exposure in routine program data was incomplete, although
data completeness improved in more recent calendar years. Additionally, actual maternal and
infant regimens were not recorded except for two facilities where we could link the child to the
maternal ART file. Notwithstanding, analyses using recorded PMTCT exposure and assumed
exposure based on year of birth both did not show an adverse effect of PMTCT exposure on
VF. Further, the resistance profile of children in a Ugandan study suggests that a large propor-
tion of children with unknown PMTCT exposure were likely exposed, supporting our sensitiv-
ity analysis approach [11].
In conclusion, our finding of no evidence of increased risk of VF among PMTCT exposed
children initiating first line EFV-based regimens is reassuring given that EFV-based regimens
have been widely used in children living with HIV, and may continue to be used until DTG is
registered and accessible for younger children, and in children requiring tuberculosis co-treat-
ment. However, the impact of extended infant NVP prophylaxis on the virologic efficacy of
subsequent EFV-based ART remains to be fully assessed.
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